View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 13, 2021

AXIM Biotechnologies develops new Covid-19 rapid neutralising antibody test

The second-generation version of AXIM’s test provides a semi-quantitative analysis of the user’s neutralising antibody levels.

AXIM Biotechnologies has developed the next-generation version of its Covid-19 Rapid Neutralizing Antibody Test.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

The company’s first rapid test is currently under review by the US Food and Drug Administration (FDA).

Antiviral antibodies are easy to detect and measure using a drop of blood.

If levels of neutralising antibodies in the blood are high enough, they protect individuals from Covid-19 infection.

Covid-19 vaccines are developed to induce antibodies against SARS-CoV-2 virus to prevent infection. However, not all antibodies neutralise the virus and provide protection from the disease.

AXIM’s rapid test distinguishes between the antibodies that bind and neutralise the SARS-CoV-2 virus and the antibodies that bind to the virus but do not neutralise it.

The latest version of the rapid neutralising antibody test shows users if they respond to the Covid-19 vaccine they receive.

It also provides a semi-quantitative analysis regarding their neutralising antibody levels in a single test.

AXIM Biotechnologies CEO John Huemoeller II said: “This new test is extremely important because it helps people know if they are protected after receiving the vaccine in just ten minutes.

“People want to make sure they are protected as vaccine immunity wanes so that they don’t develop an asymptomatic infection and transmit the virus to vulnerable populations.”

The AXIM neutralising antibody test for Covid-19 is claimed to be the first rapid test that measures the levels of functional neutralising antibodies providing protection against the SARS-CoV-2 virus.

Additionally, AXIM stated that it is developing rapid diagnostic tests to detect cancer and ophthalmological conditions, such as dry eye disease (DED), in the early stage.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network